According to American Society of Clinical Oncology–College of American Pathologists (ASCO-CAP) guidelines, HER-2 positivity is defined as a 3+ score in immuno-histochemistry (IHC) staining in ≥10% of tumor cells or a 2+ score with HER-2 gene amplification through in situ hybridization (ISH) [15]. The gene discussed is ERBB2; the disease is neoplasm.